
Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load
COVID-19 test, based on Aegea’s next-generation COVID-19 assay kit using Switch-Blocker™ technology, may provide answers that support screening and managing patients
The new COVID-19 assay is a next-generation PCR-based test using proprietary Switch-Blocker technology for viral RNA detection as well as discrimination of L- and S-strain types. As a result of this core technology, which enables robust single nucleotide discrimination, the assay has several technical advantages compared with other COVID-19 PCR assays. The assay may have the ability to evaluate sample adequacy in patients with negative results and be adapted to identify new variants of the SARS-CoV-2 virus as they emerge. It is expected to allow quantitative evaluation of viral load to better assist healthcare providers who are screening asymptomatic patients, managing patients with symptomatic infections, or evaluating patients who are recovering from COVID-19.
“This new assay further demonstrates Biocept’s commitment to COVID-19 PCR testing by expanding our COVID-19 portfolio with a differentiated LDT,” said
“Biocept is the ideal partner to validate and commercialize our new COVID-19 assay kit, as well as potential follow-on assays for different SARS-CoV-2 variants,” said
Switch-Blocker technology used in the COVID-19 test, which also is the basis for Biocept’s ultra-sensitive oncology assays, is patent protected in
About Aegea Biotechnologies
About
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005447/en/
ssung@aegeabiotech.com, 858-353-5749
Biocept Media Contact:
asampson@sampsonprgroup.com, 562-304-0301
Biocept Investor Contact:
Jcain@lhai.com, 310-691-7100
Source: